{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+once+daily&page=5", "query": { "intervention": "Placebo once daily", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 5494, "total_pages": 550, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+once+daily&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+once+daily&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-12T07:33:47.114Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04199104", "title": "A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 511, "start_date": "2020-02-05", "completion_date": "2025-03-31", "has_results": true, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-10-12T07:33:47.114Z", "location_count": 26, "location_summary": "Fresno, California • San Marcos, California • Aurora, Colorado + 22 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "San Marcos", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Farmington", "state": "Connecticut" }, { "city": "Hollywood", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04199104" }, { "nct_id": "NCT02964247", "title": "LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "liraglutide", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 303, "start_date": "2017-03-03", "completion_date": "2018-05-08", "has_results": true, "last_update_posted_date": "2020-11-17", "last_synced_at": "2026-10-12T07:33:47.114Z", "location_count": 56, "location_summary": "Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 47 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Lancaster", "state": "California" }, { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02964247" }, { "nct_id": "NCT04770389", "title": "Randomized Study of Obicetrapib in Combination With Ezetimibe", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dyslipidemias", "High Cholesterol", "Hypercholesterolemia" ], "interventions": [ { "name": "Obicetrapib 5mg", "type": "DRUG" }, { "name": "Ezetimibe 10mg", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "NewAmsterdam Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 112, "start_date": "2021-02-23", "completion_date": "2021-06-30", "has_results": true, "last_update_posted_date": "2024-04-24", "last_synced_at": "2026-10-12T07:33:47.114Z", "location_count": 3, "location_summary": "Lincoln, California • Evanston, Illinois • Houston, Texas", "locations": [ { "city": "Lincoln", "state": "California" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04770389" }, { "nct_id": "NCT01466335", "title": "An Adaptive Phase I Study to Evaluate the Safety, Efficacy and Dose Responses of Ronacaleret in Healthy Human Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bone Marrow Transplantation" ], "interventions": [ { "name": "Ronacaleret (100mg tablet)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 39, "start_date": "2011-10-27", "completion_date": "2012-03-05", "has_results": false, "last_update_posted_date": "2017-06-20", "last_synced_at": "2026-10-12T07:33:47.114Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01466335" }, { "nct_id": "NCT05736874", "title": "ACTIV-6: COVID-19 Study of Repurposed Medications - Arm C (Fluticasone)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Covid19" ], "interventions": [ { "name": "Fluticasone", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Susanna Naggie, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "ALL", "summary": "30 Years and older" }, "enrollment_count": 1407, "start_date": "2021-08-06", "completion_date": "2022-05-18", "has_results": true, "last_update_posted_date": "2023-06-18", "last_synced_at": "2026-10-12T07:33:47.114Z", "location_count": 87, "location_summary": "Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 75 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Newport Beach", "state": "California" }, { "city": "North Hollywood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05736874" }, { "nct_id": "NCT01383148", "title": "Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Non-Small-Cell Lung Carcinoma" ], "interventions": [ { "name": "TG4010", "type": "BIOLOGICAL" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Transgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 222, "start_date": "2012-04", "completion_date": "2016-07", "has_results": false, "last_update_posted_date": "2017-01-05", "last_synced_at": "2026-10-12T07:33:47.114Z", "location_count": 12, "location_summary": "Scottsdale, Arizona • Topeka, Kansas • Louisville, Kentucky + 9 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Topeka", "state": "Kansas" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Cambridge", "state": "Maryland" }, { "city": "Rockville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01383148" }, { "nct_id": "NCT00035555", "title": "Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Graft Rejection", "Kidney Transplantation", "Renal Transplantation" ], "interventions": [ { "name": "Belatacept", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Mycophenolate mofetil (MMF)", "type": "DRUG" }, { "name": "Corticosteroids", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 230, "start_date": "2001-03", "completion_date": "2012-07", "has_results": true, "last_update_posted_date": "2014-01-13", "last_synced_at": "2026-10-12T07:33:47.114Z", "location_count": 12, "location_summary": "San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 9 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00035555" }, { "nct_id": "NCT06143891", "title": "A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Graft Versus Host Disease" ], "interventions": [ { "name": "Belumosudil", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Prednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 260, "start_date": "2024-01-23", "completion_date": "2028-09-29", "has_results": false, "last_update_posted_date": "2025-10-14", "last_synced_at": "2026-10-12T07:33:47.114Z", "location_count": 24, "location_summary": "Little Rock, Arkansas • Duarte, California • San Francisco, California + 21 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Decatur", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06143891" }, { "nct_id": "NCT01106690", "title": "The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Canagliflozin", "type": "DRUG" }, { "name": "Sitagliptin", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Pioglitazone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 344, "start_date": "2010-06", "completion_date": "2012-07", "has_results": true, "last_update_posted_date": "2013-07-15", "last_synced_at": "2026-10-12T07:33:47.114Z", "location_count": 41, "location_summary": "Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Burlingame", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01106690" }, { "nct_id": "NCT05927597", "title": "A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of INS1007 in Healthy Japanese and Caucasian Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "INS1007", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Insmed Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 82, "start_date": "2019-01-09", "completion_date": "2019-08-01", "has_results": false, "last_update_posted_date": "2023-07-03", "last_synced_at": "2026-10-12T07:33:47.114Z", "location_count": 1, "location_summary": "Glendale, California", "locations": [ { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05927597" } ] }